Posaconazole + Voriconazole + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infections
Conditions
Fungal Infections, Invasive Pulmonary Aspergillosis
Trial Timeline
Sep 25, 2013 → Sep 10, 2019
NCT ID
NCT01782131About Posaconazole + Voriconazole + Placebo
Posaconazole + Voriconazole + Placebo is a phase 3 stage product being developed by Merck for Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01782131. Target conditions include Fungal Infections, Invasive Pulmonary Aspergillosis.
What happened to similar drugs?
9 of 20 similar drugs in Fungal Infections were approved
Approved (9) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01782131 | Phase 3 | Completed |
Competing Products
20 competing products in Fungal Infections